Drugs

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Drugs

Ipilimumab and Nivolumab for patients with unresected advanced Hepatocellular Carcinoma – ESMO

Photo from ESMO/LinkedIn

Jul 5, 2024, 02:30

Ipilimumab and Nivolumab for patients with unresected advanced Hepatocellular Carcinoma – ESMO

ESMO shared on LinkedIn:

“Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced Hepatocellular Carcinoma.
Read the opinion piece by Angela Lamarca on ESMO Daily Reporter.”

Source: ESMO/LinkedIn

Angela Lamarca cancer ESMO ESMO Daily Reporter hepatocellular carcinoma ipilimumab nivolumab OncoDaily Oncology

Jul 7, 2024, 18:59

Maria Babak: Clear and comprehensive breakdown of the cancer staging process using the TNM system

Jul 7, 2024, 18:39

Charles Roberts: Applications are now open for the Damon Runyon-St. Jude Pediatric Cancer Research Fellowship Award

Jul 7, 2024, 18:32

A significant perception gap between patients with Colorectal Cancer and Healthcare Professionals - ESMO

Jul 7, 2024, 18:19

Shahrin Ahmed: Efficacy of CARVYKTI in multiple myeloma

Jul 7, 2024, 17:57

Research grants available from CGA IGC

Jul 7, 2024, 17:51

Stephen V. Liu: How do we encourage colleagues and patients to wait for biomarker results?

Jul 7, 2024, 17:43

Jarushka Naidoo: ctDNA+ associates with outcomes in stage III unresectable NSCLC

Jul 7, 2024, 17:41

Miguel Bronchud: The importance of well-designed Randomized Controlled Trials

Jul 7, 2024, 17:38

Some myeloma updates by Manni Mohyuddin

Jul 7, 2024, 17:31

Alarming rise of young adult colorectal cancer

Jul 7, 2024, 17:28

Cristiane D. Bergerot: Unmet social needs in cancer care across HIC and LMIC

Jul 7, 2024, 17:19

Vicki Durston: Highlighting the Power of Patient Advocacy